Aclaris Therapeutics, Inc. (ACRS) research
Aclaris Therapeutics, Inc.- Sector
- Pharmaceuticals
- Last price
- $5.50
- As of
Aclaris Therapeutics, Inc. (ACRS): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
As of . Source: SEC EDGAR filings for ACRS. Method and limitations.
Share the ACRS intelligence card
See ACRS live in the terminal
Track ACRS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ACRS terminal, freeActive signals for ACRS
- highCONSENSUS_SELL
3 tracked funds reduced ACRS this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +63% to ACRS (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 83% of ACRS (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +182% to ACRS (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 54% of ACRS (2026Q2)
FREE, NO ACCOUNT
Every signal on ACRS, as it fires
You are seeing 5 of 25 signals recorded on ACRS since 2026-06-21.
The five above all landed on 2026-09-06. The other 20 were recorded on 3 other days. 20 of the 25 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ACRS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 00461U105 · 2026Q2 | $9.3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 00461U105 · 2026Q2 | $4.3M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 00461U105 · 2026Q2 | $2.8M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 00461U105 · 2026Q2 | $2.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00461U105 · 2026Q2 | $704K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ACRS
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ACRS against its peers
ACRS's operating margin of -975.9% ranks in the 14th percentile of 17 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | ACRS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 7.8M USD | 411M USD | 8 | 19 |
| Gross margin | n/a | 56.3% | n/a | 6 |
| Operating margin | -975.9% | 12.6% | 14 | 17 |
| Net margin | -829.6% | 1.2% | 13 | 18 |
| Return on equity | -63.0% | -3.6% | 16 | 21 |
| P / E | n/a | 13.9x | n/a | 10 |
Peers (24): ESPR, COLL, PCRX, AMPH, ALMS, ANRO, OMER, PAHC, XERS, INVA, AVIR, ANIP, BIOA, NUVB, TRVI, FULC, BHC, NKTR, OCUL, SUPN, HRMY, GPCR, SIGA, OGN. Left out: ACB (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ACRS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ACRS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ACRSand get the insider, 13F, options, and confluence read in one view.